Key Insights
The Asia-Pacific nuclear medicine market is experiencing significant expansion, fueled by the increasing incidence of chronic diseases, a growing elderly population, and advancements in imaging technology. Enhanced healthcare infrastructure and diagnostic capabilities across the region are further accelerating this growth. Key applications in oncology, cardiology, and neurology are driving substantial demand for nuclear medicine procedures. The market size in 2025 is projected to be $7.03 billion, with a Compound Annual Growth Rate (CAGR) of 8% from the base year 2025. China, Japan, India, and South Korea are primary growth drivers, with China presenting a substantial opportunity due to its large population and developing healthcare sector. Key restraints include the high cost of equipment and radioisotopes, rigorous regulatory processes, and the demand for skilled professionals. Nevertheless, the long-term outlook for the Asia-Pacific nuclear medicine market remains optimistic, with continued growth anticipated throughout the forecast period driven by the adoption of advanced diagnostics and personalized medicine. Leading companies such as GE Healthcare, Siemens Healthineers, and Lantheus Medical Imaging highlight the market's investment potential.
Asia-Pacific Nuclear Medicine Industry Market Size (In Billion)
The competitive environment features a mix of multinational corporations and specialized firms. These entities are pursuing strategic alliances, technological innovations in radiotracers and imaging systems, and expansion into emerging markets to secure market share. The robust growth of the PET segment, particularly in oncology, underscores the increasing importance of accurate diagnostic imaging for cancer management. This segment is expected to continue its strong growth trajectory, significantly contributing to overall market expansion. The development of novel radiopharmaceuticals and the integration of AI-powered diagnostic tools are poised to revolutionize the nuclear medicine sector, presenting both opportunities and challenges.
Asia-Pacific Nuclear Medicine Industry Company Market Share
Asia-Pacific Nuclear Medicine Industry: Market Analysis & Forecast 2019-2033
This comprehensive report provides an in-depth analysis of the Asia-Pacific nuclear medicine industry, offering invaluable insights for stakeholders seeking to understand market dynamics, growth trajectories, and future opportunities. Covering the period from 2019 to 2033, with a base year of 2025 and a forecast period from 2025 to 2033, this report is essential for strategic decision-making. The market value in 2025 is estimated at $XX Million.
Asia-Pacific Nuclear Medicine Industry Market Composition & Trends
The Asia-Pacific nuclear medicine market is characterized by a dynamic interplay of factors influencing its growth and evolution. Market concentration is moderate, with key players like GE Healthcare, Cardinal Health Inc, Siemens Healthineers AG, and Nordion Inc holding significant market share, estimated at a combined XX% in 2025. However, the emergence of smaller, specialized players is increasing competition. Innovation is driven by advancements in Positron Emission Tomography (PET) technology and the development of novel radiopharmaceuticals. The regulatory landscape, while evolving, presents both opportunities and challenges, particularly regarding approvals and reimbursement policies. Substitute products are limited, with nuclear medicine often providing unique diagnostic and therapeutic capabilities. End-users primarily consist of hospitals, diagnostic imaging centers, and research institutions. M&A activity has been moderate, with recent deals valued at an estimated $XX Million annually, indicating consolidation and strategic expansion within the industry.
- Market Share Distribution (2025): GE Healthcare (XX%), Cardinal Health Inc (XX%), Siemens Healthineers AG (XX%), Nordion Inc (XX%), Others (XX%).
- M&A Deal Value (2019-2024): Approximately $XX Million.
- Key Innovation Catalysts: Advancements in PET/CT technology, development of targeted radiopharmaceuticals.
- Regulatory Landscape: Varying regulations across different countries in the Asia-Pacific region.
Asia-Pacific Nuclear Medicine Industry Industry Evolution
The Asia-Pacific nuclear medicine market has witnessed significant growth between 2019 and 2024, driven primarily by increasing prevalence of chronic diseases, technological advancements, and rising healthcare expenditure. The market experienced a Compound Annual Growth Rate (CAGR) of XX% during this period. Technological advancements, such as the development of more sensitive and specific imaging modalities (like PET/MRI), have significantly improved diagnostic capabilities and enabled earlier disease detection. The growing adoption of PET scans, particularly in oncology and cardiology, has fueled market expansion. Rising disposable incomes and increasing awareness of advanced diagnostic and therapeutic options among patients have also contributed to market growth. The adoption rate of PET scans increased by XX% between 2019 and 2024, showcasing strong patient demand. Future growth is expected to be driven by further technological innovation, expansion of healthcare infrastructure, and government initiatives to improve healthcare access. The projected CAGR for 2025-2033 is XX%.
Leading Regions, Countries, or Segments in Asia-Pacific Nuclear Medicine Industry
The Oncology segment dominates the Asia-Pacific nuclear medicine market, driven by the rising incidence of cancer across the region. Within the application area, Japan and China are leading markets due to significant investments in healthcare infrastructure, a large patient population, and increasing adoption of advanced diagnostic tools.
- Key Drivers for Oncology Segment Dominance:
- High prevalence of cancer.
- Significant investments in oncology research and infrastructure.
- Government support for cancer care initiatives.
- Key Drivers for Japan and China Market Leadership:
- Large population base with high prevalence of chronic diseases.
- Strong government investments in healthcare infrastructure and advanced medical technologies.
- Growing awareness and acceptance of nuclear medicine procedures.
The PET Therapeutics segment shows strong growth potential, with increasing focus on targeted therapies and personalized medicine. Cardiology and neurology applications are also experiencing steady growth, driven by increasing prevalence of cardiovascular diseases and neurological disorders.
Asia-Pacific Nuclear Medicine Industry Product Innovations
Recent innovations have focused on improving image resolution, reducing radiation exposure, and developing more targeted radiopharmaceuticals. New PET tracers with enhanced sensitivity and specificity are improving diagnostic accuracy. The integration of artificial intelligence (AI) in image analysis is improving diagnostic efficiency and accuracy. These advancements enhance the unique selling propositions of nuclear medicine, offering precise diagnostics and effective treatment options.
Propelling Factors for Asia-Pacific Nuclear Medicine Industry Growth
Growth in the Asia-Pacific nuclear medicine market is propelled by factors including:
- Technological Advancements: Development of advanced imaging technologies like PET/MRI and improved radiopharmaceuticals.
- Increasing Prevalence of Chronic Diseases: Higher incidence of cancer, cardiovascular diseases, and neurological disorders.
- Rising Healthcare Expenditure: Increased investments in healthcare infrastructure and advanced medical technologies.
- Government Support: Government initiatives to improve healthcare access and promote the use of advanced diagnostic tools.
Obstacles in the Asia-Pacific Nuclear Medicine Industry Market
Challenges include:
- Regulatory Hurdles: Complex regulatory processes for approvals of new radiopharmaceuticals and technologies.
- High Costs: High cost of equipment and procedures limiting accessibility for some patients.
- Supply Chain Disruptions: Challenges in obtaining essential radioisotopes, impacting procedure availability.
- Competition: Increasing competition from alternative diagnostic and therapeutic modalities.
Future Opportunities in Asia-Pacific Nuclear Medicine Industry
Future opportunities lie in:
- Expanding into Untapped Markets: Targeting underserved regions with limited access to advanced diagnostic technologies.
- Developing Novel Radiopharmaceuticals: Focus on targeted therapies and personalized medicine.
- Integrating AI and Machine Learning: Improving diagnostic efficiency and accuracy.
- Telemedicine and Remote Diagnostics: Improving access to nuclear medicine services in remote areas.
Major Players in the Asia-Pacific Nuclear Medicine Industry Ecosystem
- Nordion Inc
- GE Healthcare
- Cardinal Health Inc
- Siemens Healthineers AG
- NTP Radioisotopes
- Lantheus Medical Imaging Inc
- Bracco Diagnostic Inc
- Curium
Key Developments in Asia-Pacific Nuclear Medicine Industry Industry
- May 2022: Ion Beam Applications S.A. received an order for a Proteus PLUS proton therapy system for installation in Yangzhou, China. This signifies growing investment in advanced cancer treatment technologies within the region.
- January 2022: Clario and XingImaging expanded their partnership to deliver PET imaging clinical trials in China. This collaboration boosts the development and adoption of novel therapeutics within the Chinese market.
Strategic Asia-Pacific Nuclear Medicine Industry Market Forecast
The Asia-Pacific nuclear medicine market is poised for robust growth over the forecast period (2025-2033), driven by technological advancements, increasing prevalence of chronic diseases, and rising healthcare expenditure. Continued investments in healthcare infrastructure, coupled with favorable government policies, will further fuel market expansion. The focus on personalized medicine and the development of novel radiopharmaceuticals will present significant opportunities for growth. The market is expected to reach $XX Million by 2033.
Asia-Pacific Nuclear Medicine Industry Segmentation
-
1. Product
-
1.1. Diagnostics
- 1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 1.1.2. Positron Emission Tomography (PET)
-
1.2. Therapeutics
- 1.2.1. Alpha Emitters
- 1.2.2. Beta Emitters
- 1.2.3. Brachytherapy
-
1.1. Diagnostics
-
2. Application
- 2.1. Cardiology
- 2.2. Neurology
- 2.3. Oncology
- 2.4. Other Applications
-
3. Geography
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia-Pacific
Asia-Pacific Nuclear Medicine Industry Segmentation By Geography
- 1. China
- 2. Japan
- 3. India
- 4. Australia
- 5. South Korea
- 6. Rest of Asia Pacific
Asia-Pacific Nuclear Medicine Industry Regional Market Share
Geographic Coverage of Asia-Pacific Nuclear Medicine Industry
Asia-Pacific Nuclear Medicine Industry REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 8% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Rise in Prevalence of Cancer and Cardiac Disorders; Increasing Demand for Biosimilar Drugs Due to Their Cost Effectiveness
- 3.3. Market Restrains
- 3.3.1. High Cost of the Diagnostic and Therapeutic Equipment and Procedures; Regulatory Uncertainty
- 3.4. Market Trends
- 3.4.1. Oncology Segment Expects to Register a High CAGR in the Asia-Pacific Nuclear Medicine Market Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Product
- 5.1.1. Diagnostics
- 5.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 5.1.1.2. Positron Emission Tomography (PET)
- 5.1.2. Therapeutics
- 5.1.2.1. Alpha Emitters
- 5.1.2.2. Beta Emitters
- 5.1.2.3. Brachytherapy
- 5.1.1. Diagnostics
- 5.2. Market Analysis, Insights and Forecast - by Application
- 5.2.1. Cardiology
- 5.2.2. Neurology
- 5.2.3. Oncology
- 5.2.4. Other Applications
- 5.3. Market Analysis, Insights and Forecast - by Geography
- 5.3.1. China
- 5.3.2. Japan
- 5.3.3. India
- 5.3.4. Australia
- 5.3.5. South Korea
- 5.3.6. Rest of Asia-Pacific
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. China
- 5.4.2. Japan
- 5.4.3. India
- 5.4.4. Australia
- 5.4.5. South Korea
- 5.4.6. Rest of Asia Pacific
- 5.1. Market Analysis, Insights and Forecast - by Product
- 6. China Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Product
- 6.1.1. Diagnostics
- 6.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 6.1.1.2. Positron Emission Tomography (PET)
- 6.1.2. Therapeutics
- 6.1.2.1. Alpha Emitters
- 6.1.2.2. Beta Emitters
- 6.1.2.3. Brachytherapy
- 6.1.1. Diagnostics
- 6.2. Market Analysis, Insights and Forecast - by Application
- 6.2.1. Cardiology
- 6.2.2. Neurology
- 6.2.3. Oncology
- 6.2.4. Other Applications
- 6.3. Market Analysis, Insights and Forecast - by Geography
- 6.3.1. China
- 6.3.2. Japan
- 6.3.3. India
- 6.3.4. Australia
- 6.3.5. South Korea
- 6.3.6. Rest of Asia-Pacific
- 6.1. Market Analysis, Insights and Forecast - by Product
- 7. Japan Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Product
- 7.1.1. Diagnostics
- 7.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 7.1.1.2. Positron Emission Tomography (PET)
- 7.1.2. Therapeutics
- 7.1.2.1. Alpha Emitters
- 7.1.2.2. Beta Emitters
- 7.1.2.3. Brachytherapy
- 7.1.1. Diagnostics
- 7.2. Market Analysis, Insights and Forecast - by Application
- 7.2.1. Cardiology
- 7.2.2. Neurology
- 7.2.3. Oncology
- 7.2.4. Other Applications
- 7.3. Market Analysis, Insights and Forecast - by Geography
- 7.3.1. China
- 7.3.2. Japan
- 7.3.3. India
- 7.3.4. Australia
- 7.3.5. South Korea
- 7.3.6. Rest of Asia-Pacific
- 7.1. Market Analysis, Insights and Forecast - by Product
- 8. India Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Product
- 8.1.1. Diagnostics
- 8.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 8.1.1.2. Positron Emission Tomography (PET)
- 8.1.2. Therapeutics
- 8.1.2.1. Alpha Emitters
- 8.1.2.2. Beta Emitters
- 8.1.2.3. Brachytherapy
- 8.1.1. Diagnostics
- 8.2. Market Analysis, Insights and Forecast - by Application
- 8.2.1. Cardiology
- 8.2.2. Neurology
- 8.2.3. Oncology
- 8.2.4. Other Applications
- 8.3. Market Analysis, Insights and Forecast - by Geography
- 8.3.1. China
- 8.3.2. Japan
- 8.3.3. India
- 8.3.4. Australia
- 8.3.5. South Korea
- 8.3.6. Rest of Asia-Pacific
- 8.1. Market Analysis, Insights and Forecast - by Product
- 9. Australia Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Product
- 9.1.1. Diagnostics
- 9.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 9.1.1.2. Positron Emission Tomography (PET)
- 9.1.2. Therapeutics
- 9.1.2.1. Alpha Emitters
- 9.1.2.2. Beta Emitters
- 9.1.2.3. Brachytherapy
- 9.1.1. Diagnostics
- 9.2. Market Analysis, Insights and Forecast - by Application
- 9.2.1. Cardiology
- 9.2.2. Neurology
- 9.2.3. Oncology
- 9.2.4. Other Applications
- 9.3. Market Analysis, Insights and Forecast - by Geography
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Australia
- 9.3.5. South Korea
- 9.3.6. Rest of Asia-Pacific
- 9.1. Market Analysis, Insights and Forecast - by Product
- 10. South Korea Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Product
- 10.1.1. Diagnostics
- 10.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 10.1.1.2. Positron Emission Tomography (PET)
- 10.1.2. Therapeutics
- 10.1.2.1. Alpha Emitters
- 10.1.2.2. Beta Emitters
- 10.1.2.3. Brachytherapy
- 10.1.1. Diagnostics
- 10.2. Market Analysis, Insights and Forecast - by Application
- 10.2.1. Cardiology
- 10.2.2. Neurology
- 10.2.3. Oncology
- 10.2.4. Other Applications
- 10.3. Market Analysis, Insights and Forecast - by Geography
- 10.3.1. China
- 10.3.2. Japan
- 10.3.3. India
- 10.3.4. Australia
- 10.3.5. South Korea
- 10.3.6. Rest of Asia-Pacific
- 10.1. Market Analysis, Insights and Forecast - by Product
- 11. Rest of Asia Pacific Asia-Pacific Nuclear Medicine Industry Analysis, Insights and Forecast, 2020-2032
- 11.1. Market Analysis, Insights and Forecast - by Product
- 11.1.1. Diagnostics
- 11.1.1.1. Single Photon Emission Computed Tomography (SPECT)
- 11.1.1.2. Positron Emission Tomography (PET)
- 11.1.2. Therapeutics
- 11.1.2.1. Alpha Emitters
- 11.1.2.2. Beta Emitters
- 11.1.2.3. Brachytherapy
- 11.1.1. Diagnostics
- 11.2. Market Analysis, Insights and Forecast - by Application
- 11.2.1. Cardiology
- 11.2.2. Neurology
- 11.2.3. Oncology
- 11.2.4. Other Applications
- 11.3. Market Analysis, Insights and Forecast - by Geography
- 11.3.1. China
- 11.3.2. Japan
- 11.3.3. India
- 11.3.4. Australia
- 11.3.5. South Korea
- 11.3.6. Rest of Asia-Pacific
- 11.1. Market Analysis, Insights and Forecast - by Product
- 12. Competitive Analysis
- 12.1. Market Share Analysis 2025
- 12.2. Company Profiles
- 12.2.1 Nordion Inc
- 12.2.1.1. Overview
- 12.2.1.2. Products
- 12.2.1.3. SWOT Analysis
- 12.2.1.4. Recent Developments
- 12.2.1.5. Financials (Based on Availability)
- 12.2.2 GE Healthcare
- 12.2.2.1. Overview
- 12.2.2.2. Products
- 12.2.2.3. SWOT Analysis
- 12.2.2.4. Recent Developments
- 12.2.2.5. Financials (Based on Availability)
- 12.2.3 Cardinal Health Inc
- 12.2.3.1. Overview
- 12.2.3.2. Products
- 12.2.3.3. SWOT Analysis
- 12.2.3.4. Recent Developments
- 12.2.3.5. Financials (Based on Availability)
- 12.2.4 Siemens Healthineers AG
- 12.2.4.1. Overview
- 12.2.4.2. Products
- 12.2.4.3. SWOT Analysis
- 12.2.4.4. Recent Developments
- 12.2.4.5. Financials (Based on Availability)
- 12.2.5 NTP Radioisotopes
- 12.2.5.1. Overview
- 12.2.5.2. Products
- 12.2.5.3. SWOT Analysis
- 12.2.5.4. Recent Developments
- 12.2.5.5. Financials (Based on Availability)
- 12.2.6 Lantheus Medical Imaging Inc
- 12.2.6.1. Overview
- 12.2.6.2. Products
- 12.2.6.3. SWOT Analysis
- 12.2.6.4. Recent Developments
- 12.2.6.5. Financials (Based on Availability)
- 12.2.7 Bracco Diagnostic Inc
- 12.2.7.1. Overview
- 12.2.7.2. Products
- 12.2.7.3. SWOT Analysis
- 12.2.7.4. Recent Developments
- 12.2.7.5. Financials (Based on Availability)
- 12.2.8 Curium
- 12.2.8.1. Overview
- 12.2.8.2. Products
- 12.2.8.3. SWOT Analysis
- 12.2.8.4. Recent Developments
- 12.2.8.5. Financials (Based on Availability)
- 12.2.1 Nordion Inc
List of Figures
- Figure 1: Asia-Pacific Nuclear Medicine Industry Revenue Breakdown (billion, %) by Product 2025 & 2033
- Figure 2: Asia-Pacific Nuclear Medicine Industry Share (%) by Company 2025
List of Tables
- Table 1: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 2: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 3: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 4: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Region 2020 & 2033
- Table 5: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 6: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 7: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 8: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 9: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 10: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 11: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 12: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 13: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 14: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 15: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 16: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 17: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 18: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 19: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 20: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 21: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 22: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 23: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 24: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Country 2020 & 2033
- Table 25: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Product 2020 & 2033
- Table 26: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Application 2020 & 2033
- Table 27: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Geography 2020 & 2033
- Table 28: Asia-Pacific Nuclear Medicine Industry Revenue billion Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Asia-Pacific Nuclear Medicine Industry?
The projected CAGR is approximately 8%.
2. Which companies are prominent players in the Asia-Pacific Nuclear Medicine Industry?
Key companies in the market include Nordion Inc, GE Healthcare, Cardinal Health Inc, Siemens Healthineers AG, NTP Radioisotopes, Lantheus Medical Imaging Inc, Bracco Diagnostic Inc, Curium.
3. What are the main segments of the Asia-Pacific Nuclear Medicine Industry?
The market segments include Product, Application, Geography.
4. Can you provide details about the market size?
The market size is estimated to be USD 7.03 billion as of 2022.
5. What are some drivers contributing to market growth?
Rise in Prevalence of Cancer and Cardiac Disorders; Increasing Demand for Biosimilar Drugs Due to Their Cost Effectiveness.
6. What are the notable trends driving market growth?
Oncology Segment Expects to Register a High CAGR in the Asia-Pacific Nuclear Medicine Market Over the Forecast Period.
7. Are there any restraints impacting market growth?
High Cost of the Diagnostic and Therapeutic Equipment and Procedures; Regulatory Uncertainty.
8. Can you provide examples of recent developments in the market?
In May 2022, Ion Beam Applications S.A. received an order from CGN Medical Technologies for a Proteus PLUS proton therapy system to be installed in Yangzhou, China.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in billion.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Asia-Pacific Nuclear Medicine Industry," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Asia-Pacific Nuclear Medicine Industry report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Asia-Pacific Nuclear Medicine Industry?
To stay informed about further developments, trends, and reports in the Asia-Pacific Nuclear Medicine Industry, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence